The study group was composed of 670 patients. The average age at diagnosis was 47 years; 90% (602) had undergone total thyroidectomy, 31% (207) had undergone lymph node dissection, and 43% (288) had received radioactive iodine therapy. Cancer characteristics included the following: primary cancer with an average size of 1.2 cm, vascular invasion in 11.3% (76), extrathyroidal extension in 26.3% (176), multiple cancers in 30% (200), presence of spread to the lymph nodes in 18% (121) and spread outside of the neck in 0.7%.
Among these patients, 2015 risk stratification yielded 61% in the low-risk group, 29% in the intermediate-risk group, and 10% in the high-risk group. Using the 2025 risk system, these patients were categorized as 48% low risk, 22% low–intermediate risk, 19% intermediate–high risk, and 12% high risk. Overall, the proportion of patients with low risk classification decreased by 22%, intermediate risk (composed of low–intermediate and intermediate– high risk classes) increased by 42%, and high risk increased by 15%.
There was no difference in persistent cancer among 2015 and 2025 low-risk groups (4.1% vs. 4.9%). The 2025 low–intermediate-risk group had lower persistent cancer compared to 2015 intermediate-risk (12.2% vs. 22.7%), and persistent cancer was similar between the 2015 intermediate-risk and 2025 intermediate–high-risk groups (22.7% vs. 22.1%) as well as between the 2015 and 2025 high-risk groups (47.8% vs. 48).
WHAT ARE THE IMPLICATIONS OF THIS STUDY?
This study shows that the risk stratification system in the 2025 American Thyroid Association guidelines for thyroid cancer defines a clinically meaningful low-intermediate risk category. However, the reclassification of 2015 low-risk patients to 2025 low-intermediate risk does not necessarily indicate benefit from more intensive therapy. The new categorizations also may have an impact on how patients perceive their disease and may add a layer of anxiety to those reclassified to a higher risk category.
— Alan P. Farwell, MD